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OBJECTIVES: To estimate the cost-effectiveness of 
mirtazapine, compared to ﬂuoxetine, in the management
of moderate and severe depression among outpatients in
Hungary, from the society and Sickfund (OEP) perspec-
tive. METHODS: The economic analysis was based on
clinical differences obtained from a six-week comparative
trial with mirtazapine and ﬂuoxetine, which were 
extrapolated to six months using assumptions derived
from the literature. Decision models of the treatment
paths and associated resource use were developed from
clinical trial data, interviews with a Hungarian Delphi
Panel (comprising of nine psychiatrists working in the
outpatient setting) and published literature and were used
to estimate the costs to society and to the Sickfund over
a treatment period of six months. RESULTS: The total
cost to Hungarian society was HUF 311,255 per 
mirtazapine-treated patient, compared to HUF 412,740
per ﬂuoxetine-treated patient. Indirect costs (i.e. produc-
tivity loss) emerged as the main cost driver. In contrast
the acquisition cost of antidepressants accounted for a
minor part of the total costs. The total medical costs for
the Sickfund were HUF 4,941 higher with mirtazapine
than with ﬂuoxetine (resp. HUF 107,429 vs. HUF
102,488). Using mirtazapine instead of ﬂuoxetine for six
months increased the proportion of successfully treated
patients by 22% (from 15.6% to 19.01%). Consequently,
the expected direct cost per patient successfully treated
with mirtazapine was HUF 563,065 compared to HUF
657,029 for a ﬂuoxetine-treated patient from the Sick-
fund perspective. The ICER for mirtazapine in compari-
son to ﬂuoxetine is HUF 141,971. CONCLUSIONS:
Since the ICER is lower than the ACER with ﬂuoxetine
(i.e. HUF 657,029) it might be concluded that treatment
with mirtazapine is more cost-effective than with ﬂuoxe-
tine from a Sickfund perspective. From a society per-
spective mirtazapine appeared to be a dominant
treatment over ﬂuoxetine: a higher proportion of suc-
cessfully treated patients for a lower total cost.
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OBJECTIVES: Frequently economic evaluations of health
technologies incorporate econometric models into the
decision making process. CCOHTA published in 1999 
a transparent model in ADHD that has been adapted 
to assess the impact of incorporating parent-rated out-
comes using CCOHTA’s existing methodology. The ad-
apted model also estimates the incremental impact 
from Concerta OROS, a new OD formulation of
methylphenidate (MPH), used over MPH immediate
release (MPH-IR) and behavioural treatment (BT).
METHODS: First, the original model was re-constructed
and validated to ensure all assumptions and calculations
were incorporated correctly. Next, the model was
adapted to include the following treatment arms—Con-
certa OROS 30mg/day OD, MPH-IR 30mg/day TID, BT.
Most assumptions/ data from the original model were
maintained except for the following: weighted mean dif-
ference (WMD) of parent ratings on the Conners IOWA
Inattention/Overactivity subscale (IOWA I/O) were used
in place of Conners Teacher Rating Scale (CTRS) hyper-
activity index; all patients received behavioural interven-
tions for a full year versus 6 months for those
non-compliant to treatment; compliance rates were ﬁxed
based on literature; outcomes data came from published
double blind, double dummy cross-over trial comparing
Concerta OROS to MPH-IR to placebo (n = 68). Effec-
tiveness was expressed in one point gain in IOWA I/O (=
clinically relevant improvement). Analysis was conducted
using DATA 3.5 by TREEAge. RESULTS: MPH-IR and
Concerta OROS resulted in increases in both annual costs
(+$600 CDN, +$713CDN respectively) and effectiveness
(+0.71 point gain, +1.44 point gain respectively) com-
pared to BT. Incremental cost-effectiveness ratios were
$851/one point gain in IOWA I/O and $496/one point
gain in IOWA I/O for MPH-IR and Concerta OROS
respectively. CONCLUSIONS: Parent ratings can be
adopted within economic models of ADHD. Under model
assumptions, using parent generated outcome ratings, a
combination of behavioural interventions and Concerta
OROS dominated MPH-IR treatment. Further sensitivity
analysis and drawbacks will be discussed.
